# Actio Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/actio-biosciences

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.actiobiosciences.com
- Total disclosed funding: $102M
- Latest round: Series B (Jun 18, 2025)
- Investors on record: 6

## About

Based in California, US, and founded in 2021 by CEO David Goldstein and co-founder John McHutchison, Actio Biosciences, Inc. operates as a research and development company developing genomics and precision medicine for rare and common diseases. In June 2025, Actio Biosciences, Inc. raised USD 66 million in series B funding co-led by new investor Regeneron Ventures and returning investor Deerfield Management, with participation from other returning investors Canaan Partners, Droia Ventures, and Euclidean Capital. Actio Biosciences, Inc. provides precision medicine for therapeutics that target shared genetics in rare and common diseases. The company offers mutant characterizations services such as functional analysis of pathogenic mutations, disease relevant assays, and direction of modulation. In addition, the firm provides preclinical insights, rare disease trials, and leveraging learnings from monogenic rare diseases. As of 2023, the company specializes in bioinformatics, biology, biotechnology research and chemistry. The company will use the June 2025 funding for the development of its ABS-1230 and ABS-0871.

## Funding rounds

- Series B, Jun 18, 2025, $66M — Canaan Partners, Deerfield Management, Euclidean Capital, Droia Ventures, Regeneron Ventures
- Series A, Aug 7, 2023, $36M — Canaan Partners, Deerfield Management, EcoR1 Capital, Euclidean Capital, Droia Ventures
- Seed, May 1, 2022 — Deerfield Management, EcoR1 Capital

## Investors

- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Seed, Series A, Series B
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Seed, Series A
- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series A, Series B
- Euclidean Capital — Series A, Series B
- Droia Ventures (https://capitalatlas.ai/funds/droia-ventures) — Series A, Series B
- Regeneron Ventures (https://capitalatlas.ai/funds/regeneron-ventures) — Series B